VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer, announced today that Ms. Lota S. Zoth, CPA, has joined the Company’s Board of Directors.
